TL;DR: AYR Wellness (OTC: AYRWF) enters the second half of 2026 with its largest market generating meaningful recreational cannabis revenue, a structural 280E cost tailwind from April’s federal medical rescheduling, and a deleveraging balance sheet that has materially improved operator visibility. With DEA adult-use rescheduling hearings approaching a record close, AYR sits at an inflection point that institutional cannabis investors should monitor closely heading into Monday’s session.
Market Analysis
AYR Wellness operates 89 cannabis dispensaries across eight states, with its largest concentration in Florida — the third-largest cannabis market in the United States by population. Florida’s November 2024 adult-use ballot initiative failure did not derail AYR’s Florida thesis; the company has instead leaned into its deep medical retail infrastructure, capturing incremental volume from out-of-state visitors and medical program expansion while maintaining per-unit margins that outpace several larger multi-state operators (MSOs).
The more significant near-term lever is the 280E tax reform that took effect following the DEA’s April 2026 federal medical rescheduling. Under prior 280E treatment, cannabis operators were denied standard business deductions under the Internal Revenue Code, resulting in effective tax rates that routinely exceeded 70 percent of pre-tax income. With Schedule III status now in force for medical cannabis, AYR’s blended effective tax rate has already begun declining in Q2 2026 — a tailwind management expects to accelerate in the back half of the year.
On the revenue side, AYR reported Q1 2026 net revenue of approximately $119 million, down modestly year-over-year as the company navigated Florida pricing compression and selective store optimization in Pennsylvania. However, adjusted EBITDA margins held above 20 percent — an important threshold that signals operational efficiency even in a challenging pricing environment. The Q2 2026 print, expected in late July, will be the first full quarter reflecting 280E relief and represents a critical data point for the operator’s recovery thesis.
AYR’s equity trades on the OTC market under the ticker AYRWF, limiting institutional access but positioning the name for meaningful re-rating should federal cannabis banking reform advance — a development that would allow uplisting to a major exchange. Investors tracking cannabis equities through the cannabis stock tracker will note that AYRWF has lagged larger-cap peers like GTBIF and CURLF year-to-date, creating a potential relative-value entry for accounts with OTC execution capability.
Regulatory and Market Context
The broader regulatory backdrop continues to evolve in AYR’s favor. The Schedule III medical rescheduling that took effect in April was Phase 1 of a two-phase federal reclassification process. Phase 2 — covering adult-use cannabis — is currently working through the DEA’s formal hearing record, with the administrative law judge expected to issue recommended findings before year-end. A favorable outcome would extend 280E relief to adult-use sales across all of AYR’s markets, representing a second, larger tax benefit that has not been priced into consensus estimates.
Meanwhile, the SAFER Banking Act has advanced further through committee in the current congressional session than in any prior iteration. The legislation would allow cannabis operators to access federally regulated banking services, reducing cash handling costs and enabling more efficient capital allocation. For AYR, which maintains a relatively complex debt structure with Canadian-market convertible notes, improved banking access would meaningfully reduce administrative overhead and potentially refinancing costs.
State-level dynamics also favor AYR’s positioning. New Jersey — where the company operates eight dispensaries — continues to generate strong adult-use volumes following its 2022 recreational launch, and the market has largely absorbed the initial supply-side compression that characterized 2023 and 2024. Maryland’s adult-use market, which launched in mid-2023, has matured into a reliable revenue contributor. Combined, AYR’s Northeast corridor operations provide a counterbalance to any near-term Florida softness.
Conclusion: What to Watch Heading Into Monday
Sunday’s equity markets close sets up a Monday open that cannabis investors will watch through the lens of the week’s regulatory calendar. No major DEA hearing dates are scheduled for the coming week, but the House floor calendar carries the SAFER Banking Act as a potential vote item — a catalyst that could move MSOS-constituent names including AYRWF with limited warning.
For AYR specifically, the 90-day window between now and the Q2 2026 earnings release will be defined by two variables: Florida dispensary-level comps as the summer tourism season peaks, and any incremental 280E guidance management provides on the savings run rate. Both inputs have potential to shift the consensus EBITDA forecast materially.
At current OTC valuations, AYR Wellness trades at an enterprise value-to-forward-EBITDA multiple that represents a discount to MSO peers with comparable operational scale. The discount reflects legitimate concerns — OTC listing limitations, balance sheet leverage, and execution risk in a price-compressed market. But the convergence of 280E relief, potential banking reform, and a Q2 earnings catalyst makes AYR a name worth tracking closely as the second half of 2026 takes shape.